Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Comparison of Universal Versus Age-Restricted Screening of Colorectal Tumors for Lynch Syndrome Using Mismatch Repair Immunohistochemistry: A Cohort Study.

Li D, Hoodfar E, Jiang SF, Udaltsova N, Pham NP, Jodesty Y, Armstrong MA, Hung YY, Baker RJ, Postlethwaite D, Ladabaum U, Levin TR, Corley DA, Bergoffen J.

Ann Intern Med. 2019 Jul 2;171(1):19-26. doi: 10.7326/M18-3316. Epub 2019 Jun 11.

PMID:
31181578
2.

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection.

Selby K, Levin TR, Corley DA.

Ann Intern Med. 2019 May 21;170(10):736-737. doi: 10.7326/L19-0095. No abstract available.

PMID:
31108529
3.

Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study.

Selby K, Jensen CD, Zhao WK, Lee JK, Slam A, Schottinger JE, Bacchetti P, Levin TR, Corley DA.

Clin Transl Gastroenterol. 2019 Feb;10(2):e00010. doi: 10.14309/ctg.0000000000000010.

4.

Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings.

Lee JK, Jensen CD, Levin TR, Zauber AG, Schottinger JE, Quinn VP, Udaltsova N, Zhao WK, Fireman BH, Quesenberry CP, Doubeni CA, Corley DA.

JAMA Intern Med. 2019 Feb 1;179(2):153-160. doi: 10.1001/jamainternmed.2018.5565.

PMID:
30556824
5.

In Screening for Colorectal Cancer, Is the FIT Right for the Right Side of the Colon?

Doubeni CA, Levin TR.

Ann Intern Med. 2018 Nov 6;169(9):650-651. doi: 10.7326/M18-2444. Epub 2018 Oct 2. No abstract available.

PMID:
30285038
6.

Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death.

Doubeni CA, Fedewa SA, Levin TR, Jensen CD, Saia C, Zebrowski AM, Quinn VP, Rendle KA, Zauber AG, Becerra-Culqui TA, Mehta SJ, Fletcher RH, Schottinger J, Corley DA.

Gastroenterology. 2019 Jan;156(1):63-74.e6. doi: 10.1053/j.gastro.2018.09.040. Epub 2018 Sep 27.

PMID:
30268788
7.

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Selby K, Jensen CD, Lee JK, Doubeni CA, Schottinger JE, Zhao WK, Chubak J, Halm E, Ghai NR, Contreras R, Skinner C, Kamineni A, Levin TR, Corley DA.

Ann Intern Med. 2018 Oct 2;169(7):439-447. doi: 10.7326/M18-0244. Epub 2018 Sep 18.

8.

Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening.

Ghai NR, Jensen CD, Corley DA, Doubeni CA, Schottinger JE, Zauber AG, Lee AT, Contreras R, Levin TR, Lee JK, Quinn VP.

Clin Transl Gastroenterol. 2018 Sep 21;9(9):186. doi: 10.1038/s41424-018-0051-2.

9.

Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers.

Tollivoro TA, Jensen CD, Marks AR, Zhao WK, Schottinger JE, Quinn VP, Ghai NR, Zauber AG, Doubeni CA, Levin TR, Fireman B, Quesenberry CP, Corley DA.

Gastrointest Endosc. 2019 Jan;89(1):168-176.e3. doi: 10.1016/j.gie.2018.08.023. Epub 2018 Aug 23.

PMID:
30144415
10.

Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population.

Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG, Lee JK, Zhao WK, Udaltsova N, Ghai NR, Lee AT, Quesenberry CP, Fireman BH, Doubeni CA.

Gastroenterology. 2018 Nov;155(5):1383-1391.e5. doi: 10.1053/j.gastro.2018.07.017. Epub 2018 Jul 19.

PMID:
30031768
11.

Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal Immunochemical Test.

Smith DH, O'Keeffe Rosetti M, Mosen DM, Rosales AG, Keast E, Perrin N, Feldstein AC, Levin TR, Liles EG.

Popul Health Manag. 2019 Feb;22(1):83-89. doi: 10.1089/pop.2018.0008. Epub 2018 Jun 21.

PMID:
29927702
12.

Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.

Liles EG, Perrin N, Rosales AG, Smith DH, Feldstein AC, Mosen DM, Levin TR.

BMC Cancer. 2018 May 2;18(1):509. doi: 10.1186/s12885-018-4402-x.

13.

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review.

Selby K, Baumgartner C, Levin TR, Doubeni CA, Zauber AG, Schottinger J, Jensen CD, Lee JK, Corley DA.

Ann Intern Med. 2017 Oct 17;167(8):565-575. doi: 10.7326/M17-1361. Epub 2017 Oct 10. Review.

14.

A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.

Shapiro JA, Bobo JK, Church TR, Rex DK, Chovnick G, Thompson TD, Zauber AG, Lieberman D, Levin TR, Joseph DA, Nadel MR.

Am J Gastroenterol. 2017 Nov;112(11):1728-1735. doi: 10.1038/ajg.2017.285. Epub 2017 Oct 10.

15.

Colorectal Cancer Screening: Money Isn't Everything . . . But It Helps!

Levin TR.

Gastroenterology. 2017 Nov;153(5):1181-1183. doi: 10.1053/j.gastro.2017.09.026. Epub 2017 Oct 4. No abstract available.

PMID:
28987422
16.

Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing.

Lee JK, Jensen CD, Levin TR, Zauber AG, Doubeni CA, Zhao WK, Corley DA.

J Clin Gastroenterol. 2019 Jan;53(1):e25-e30. doi: 10.1097/MCG.0000000000000929.

PMID:
28906424
17.

Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcare setting.

Li D, Woolfrey J, Jiang SF, Jensen CD, Zhao WK, Kakar S, Santamaria M, Rumore G, Armstrong MA, Postlethwaite D, Corley DA, Levin TR.

Gastrointest Endosc. 2018 Mar;87(3):755-765.e1. doi: 10.1016/j.gie.2017.08.012. Epub 2017 Aug 24.

PMID:
28843582
18.

Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test.

Doubeni CA, Corley DA, Levin TR.

JAMA. 2017 Aug 1;318(5):483. doi: 10.1001/jama.2017.9312. No abstract available.

19.

Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.

Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ.

Gastroenterology. 2017 Jul;153(1):307-323. doi: 10.1053/j.gastro.2017.05.013. Epub 2017 Jun 9.

PMID:
28600072
20.

Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer.

Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ.

Gastrointest Endosc. 2017 Jul;86(1):18-33. doi: 10.1016/j.gie.2017.04.003. Epub 2017 Jun 6. No abstract available.

PMID:
28600070
21.

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer.

Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ.

Am J Gastroenterol. 2017 Jul;112(7):1016-1030. doi: 10.1038/ajg.2017.174. Epub 2017 Jun 6. Review.

PMID:
28555630
22.

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Schottinger JE, Marks AR, Zhao WK, Ghai NR, Lee AT, Contreras R, Quesenberry CP, Fireman BH, Levin TR.

JAMA. 2017 Apr 25;317(16):1631-1641. doi: 10.1001/jama.2017.3634.

23.

Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program.

Fedewa SA, Corley DA, Jensen CD, Zhao W, Goodman M, Jemal A, Ward KC, Levin TR, Doubeni CA.

Am J Prev Med. 2017 Sep;53(3):335-344. doi: 10.1016/j.amepre.2017.02.018. Epub 2017 Apr 17.

24.

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ, Rex DK.

Gastroenterology. 2017 May;152(6):1605-1614. doi: 10.1053/j.gastro.2017.02.011. Epub 2017 Mar 28. Review.

PMID:
28363489
25.

Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer.

Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ, Rex DK.

Gastrointest Endosc. 2017 May;85(5):873-882. doi: 10.1016/j.gie.2017.03.015. Epub 2017 Mar 28. No abstract available.

PMID:
28363411
26.

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-society Task Force on Colorectal Cancer.

Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ, Rex DK.

J Pediatr Gastroenterol Nutr. 2017 May;64(5):836-843. doi: 10.1097/MPG.0000000000001578. No abstract available.

PMID:
28353469
27.

Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ, Rex DK.

Am J Gastroenterol. 2017 May;112(5):682-690. doi: 10.1038/ajg.2017.105. Epub 2017 Mar 28.

PMID:
28349994
28.

The Best Laid Plans: Adaptation is an Essential Part of Going From Efficacy Research to Program Implementation.

Levin TR.

Gastroenterology. 2017 Mar;152(4):693-694. doi: 10.1053/j.gastro.2017.01.025. Epub 2017 Jan 29. No abstract available.

PMID:
28143771
29.

Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Doubeni CA, Jensen CD, Fedewa SA, Quinn VP, Zauber AG, Schottinger JE, Corley DA, Levin TR.

J Am Board Fam Med. 2016 Nov 12;29(6):672-681. doi: 10.3122/jabfm.2016.06.160060.

30.

In simulation modelling, there are multiple ways to effectively screen for colorectal cancer.

Levin TR.

Evid Based Med. 2017 Apr;22(2):59. doi: 10.1136/ebmed-2016-110521. Epub 2017 Jan 10. No abstract available.

PMID:
28073866
31.

Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

Levin TR, Corley DA, Jensen CD, Marks AR, Zhao WK, Zebrowski AM, Quinn VP, Browne LW, Taylor WR, Ahlquist DA, Lidgard GP, Berger BM.

Dig Dis Sci. 2017 Mar;62(3):678-688. doi: 10.1007/s10620-016-4433-6. Epub 2017 Jan 2.

32.

Beyond Colonoscopy: The Role of Alternative Screening Tests for Colorectal Cancer in Your Practice.

Levin TR.

Am J Gastroenterol. 2017 Jan;112(1):8-10. doi: 10.1038/ajg.2016.504. Epub 2016 Nov 1. No abstract available.

PMID:
27801886
33.

Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study.

Doubeni CA, Corley DA, Quinn VP, Jensen CD, Zauber AG, Goodman M, Johnson JR, Mehta SJ, Becerra TA, Zhao WK, Schottinger J, Doria-Rose VP, Levin TR, Weiss NS, Fletcher RH.

Gut. 2018 Feb;67(2):291-298. doi: 10.1136/gutjnl-2016-312712. Epub 2016 Oct 12.

34.

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK.

Gastroenterology. 2017 Apr;152(5):1217-1237.e3. doi: 10.1053/j.gastro.2016.08.053. Epub 2016 Oct 19. Review.

PMID:
27769517
35.

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer.

Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK.

Gastrointest Endosc. 2017 Jan;85(1):2-21.e3. doi: 10.1016/j.gie.2016.09.025. Epub 2016 Oct 18. Review. No abstract available.

PMID:
27769516
36.

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.

Mehta SJ, Jensen CD, Quinn VP, Schottinger JE, Zauber AG, Meester R, Laiyemo AO, Fedewa S, Goodman M, Fletcher RH, Levin TR, Corley DA, Doubeni CA.

J Gen Intern Med. 2016 Nov;31(11):1323-1330. doi: 10.1007/s11606-016-3792-1. Epub 2016 Jul 13.

37.

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK.

Am J Gastroenterol. 2017 Jan;112(1):37-53. doi: 10.1038/ajg.2016.492. Epub 2016 Oct 18. Review.

PMID:
27753435
38.

Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting.

Lee A, Jensen CD, Marks AR, Zhao WK, Doubeni CA, Zauber AG, Quinn VP, Levin TR, Corley DA.

Gastrointest Endosc. 2017 Mar;85(3):601-610.e2. doi: 10.1016/j.gie.2016.09.033. Epub 2016 Oct 1.

39.

Shifts in the Fecal Microbiota Associated with Adenomatous Polyps.

Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, Rex DK, Ahnen DJ, Lance P, Ahlquist DA, Chia N.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):85-94. doi: 10.1158/1055-9965.EPI-16-0337. Epub 2016 Sep 26.

40.

Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.

Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1445-1451.e8. doi: 10.1016/j.cgh.2016.05.017. Epub 2016 May 19. Erratum in: Clin Gastroenterol Hepatol. 2018 May;16(5):787. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1365. Abstract corrected.

41.

Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone.

Levin TR.

Gastrointest Endosc. 2016 Mar;83(3):552-4. doi: 10.1016/j.gie.2015.08.023. No abstract available.

PMID:
26897047
42.

Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.

Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK; United States Multi-Society Task Force on Colorectal Cancer.

Gastroenterology. 2016 Mar;150(3):758-768.e11. doi: 10.1053/j.gastro.2016.01.001. Epub 2016 Feb 10. Review.

PMID:
26892199
43.

Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer.

Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK.

Am J Gastroenterol. 2016 Mar;111(3):337-46; quiz 347. doi: 10.1038/ajg.2016.22. Epub 2016 Feb 12.

PMID:
26871541
44.

Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems.

Chubak J, Garcia MP, Burnett-Hartman AN, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM; PROSPR consortium.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):344-50. doi: 10.1158/1055-9965.EPI-15-0470.

45.

Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN, Quesenberry CP, Levin TR, Mysliwiec PA.

Ann Intern Med. 2016 Apr 5;164(7):456-63. doi: 10.7326/M15-0983. Epub 2016 Jan 26.

46.

Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer.

Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK.

Gastrointest Endosc. 2016 Mar;83(3):489-98.e10. doi: 10.1016/j.gie.2016.01.020. Epub 2016 Jan 21. Review. No abstract available.

PMID:
26802191
47.

Factors influencing variation in physician adenoma detection rates: a theory-based approach for performance improvement.

Atkins L, Hunkeler EM, Jensen CD, Michie S, Lee JK, Doubeni CA, Zauber AG, Levin TR, Quinn VP, Corley DA.

Gastrointest Endosc. 2016 Mar;83(3):617-26.e2. doi: 10.1016/j.gie.2015.08.075. Epub 2015 Sep 11.

48.

Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model.

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M.

JAMA. 2015 Jun 16;313(23):2349-58. doi: 10.1001/jama.2015.6251.

49.

Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.

Henry CJ, Sedjo RL, Rozhok A, Salstrom J, Ahnen D, Levin TR, D'Agostino R Jr, Haffner S, DeGregori J, Byers T.

BMC Cancer. 2015 Mar 14;15:123. doi: 10.1186/s12885-015-1115-2.

50.

CDC Grand Rounds: the future of cancer screening.

Thomas CC, Richards TB, Plescia M, Wong FL, Ballard R, Levin TR, Calonge BN, Brawley OW, Iskander J; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Apr 3;64(12):324-7.

Supplemental Content

Loading ...
Support Center